A case of severe opioid and methamphetamine use disorder in a 14 year old.
Humans
Adolescent
Opioid-Related Disorders
Female
Buprenorphine
/ therapeutic use
Amphetamine-Related Disorders
Opiate Substitution Treatment
/ methods
Narcotic Antagonists
/ administration & dosage
Drug Overdose
Methamphetamine
Fentanyl
/ administration & dosage
Medication Adherence
Opiate Overdose
Journal
Addiction science & clinical practice
ISSN: 1940-0640
Titre abrégé: Addict Sci Clin Pract
Pays: England
ID NLM: 101316917
Informations de publication
Date de publication:
19 Jul 2024
19 Jul 2024
Historique:
received:
22
01
2024
accepted:
08
07
2024
medline:
20
7
2024
pubmed:
20
7
2024
entrez:
19
7
2024
Statut:
epublish
Résumé
We present the case of a 14-year-old who established care at our primary care clinic after hospitalization for unintentional fentanyl overdose. They were diagnosed with severe opioid use disorder (OUD) and stimulant use disorder (StUD) and initiated buprenorphine while inpatient. They were then transitioned to the only known outpatient primary care clinic in her county who was actively providing medications for opioid use disorder (MOUD) in adolescents.At the first visit, they reported a history of 20 overdoses, struggling with adherence to buprenorphine and continued opioid cravings. An overdose safety plan was reviewed with them and their parent including providing them naloxone kits, fentanyl test strips, and education handout sheets. Due to their significant overdose history and adherence challenges with sublingual buprenorphine, they were started on long-acting injectable buprenorphine (LAIB) with weekly provider visits and urine toxicology screening. In collaboration with the treatment team, they initiated behavioral treatment with contingency management (CM), with incentives for appointment completion, expected urine results, and successful medication administration. Over the next 19 months, and to date, they have increasingly engaged with care and have remained abstinent. LAIB may be an appealing alternative for adolescents with OUD to improve adherence and reduce risk of recurrent use and overdose. Adjunctive treatment with CM may improve retention in MOUD and have the benefit of treating StUD. There is a need for further research to explore innovative, community-based treatment for youth with OUD.
Identifiants
pubmed: 39030629
doi: 10.1186/s13722-024-00487-1
pii: 10.1186/s13722-024-00487-1
doi:
Substances chimiques
Buprenorphine
40D3SCR4GZ
Narcotic Antagonists
0
Methamphetamine
44RAL3456C
Fentanyl
UF599785JZ
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
54Informations de copyright
© 2024. The Author(s).
Références
Friedman J, Godvin M, Shover CL, Gone JP, Hansen H, Schriger DL. Trends in Drug Overdose deaths among US adolescents, January 2010 to June 2021. JAMA. 2022;327(14):1398–400.
doi: 10.1001/jama.2022.2847
pubmed: 35412573
pmcid: 9006103
Lim JK, Earlywine JJ, Bagley SM, Marshall BDL, Hadland SE. Polysubstance involvement in opioid overdose deaths in adolescents and young adults, 1999–2018. JAMA Pediatr. 2021;175(2):194–6.
doi: 10.1001/jamapediatrics.2020.5035
pubmed: 33226412
Robinson CA, Wilson JD. Management of Opioid Misuse and Opioid Use disorders among Youth. Pediatrics. 2020;145(Suppl 2):S153–64.
doi: 10.1542/peds.2019-2056C
pubmed: 32358206
Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of medications in the treatment of Addiction Involving Opioid Use. J Addict Med. 2015;9(5):358–67.
doi: 10.1097/ADM.0000000000000166
pubmed: 26406300
pmcid: 4605275
Committee on Substance Use and Prevention. Medication-assisted treatment of adolescents with opioid Use disorders. Pediatrics. 2016;138(3):e20161893.
doi: 10.1542/peds.2016-1893
Hadland SE, Aalsma MC, Akgül S, Alinsky RH, Bruner A, Chadi N, et al. Medication for adolescents and young adults with opioid Use Disorder. J Adolesc Health off Publ Soc Adolesc Med. 2021;68(3):632–6.
doi: 10.1016/j.jadohealth.2020.12.129
AACAP. Opioid Use Disorder Treatment for Youth. [cited 2024 May 24]. https://www.aacap.org/AACAP/Policy_Statements/2020/Opioid_Use_Disorder_Treatment_Youth.aspx .
Terranella A, Guy GP, Mikosz C. Buprenorphine Dispensing among Youth aged ≤ 19 years in the United States: 2015–2020. Pediatrics. 2023;151(2):e2022058755.
doi: 10.1542/peds.2022-058755
pubmed: 36691760
Bolívar HA, Klemperer EM, Coleman SRM, DeSarno M, Skelly JM, Higgins ST. Contingency management for patients receiving medication for opioid use disorder: a systematic review and Meta-analysis. JAMA Psychiatry. 2021;78(10):1092–102.
doi: 10.1001/jamapsychiatry.2021.1969
pubmed: 34347030
Stanger C, Budney AJ. Contingency management: using incentives to improve outcomes for adolescent substance Use disorders. Pediatr Clin North Am. 2019;66(6):1183–92.
doi: 10.1016/j.pcl.2019.08.007
pubmed: 31679606
pmcid: 6834344
Prendergast M, Podus D, Finney J, Greenwell L, Roll J. Contingency management for treatment of substance use disorders: a meta-analysis. Addict Abingdon Engl. 2006;101(11):1546–60.
doi: 10.1111/j.1360-0443.2006.01581.x
Hadland SE, Burr WH, Zoucha K, Somberg CA, Camenga DR. Treating adolescent opioid Use Disorder in Primary Care. JAMA Pediatr. 2024;178(4):414–6.
doi: 10.1001/jamapediatrics.2023.6493
pubmed: 38407892